BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31196455)

  • 1. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer.
    Atkins KM; Rawal B; Chaunzwa TL; Lamba N; Bitterman DS; Williams CL; Kozono DE; Baldini EH; Chen AB; Nguyen PL; D'Amico AV; Nohria A; Hoffmann U; Aerts HJWL; Mak RH
    J Am Coll Cardiol; 2019 Jun; 73(23):2976-2987. PubMed ID: 31196455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer.
    Atkins KM; Chaunzwa TL; Lamba N; Bitterman DS; Rawal B; Bredfeldt J; Williams CL; Kozono DE; Baldini EH; Nohria A; Hoffmann U; Aerts HJWL; Mak RH
    JAMA Oncol; 2021 Feb; 7(2):206-219. PubMed ID: 33331883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy.
    Atkins KM; Bitterman DS; Chaunzwa TL; Kozono DE; Baldini EH; Aerts HJWL; Tamarappoo BK; Hoffmann U; Nohria A; Mak RH
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1473-1479. PubMed ID: 33713743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
    Dess RT; Sun Y; Matuszak MM; Sun G; Soni PD; Bazzi L; Murthy VL; Hearn JWD; Kong FM; Kalemkerian GP; Hayman JA; Ten Haken RK; Lawrence TS; Schipper MJ; Jolly S
    J Clin Oncol; 2017 May; 35(13):1395-1402. PubMed ID: 28301264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer.
    Atkins KM; Bitterman DS; Chaunzwa TL; Williams CL; Rahman R; Kozono DE; Baldini EH; Aerts HJWL; Tamarappoo BK; Hoffmann U; Nohria A; Mak RH
    Pract Radiat Oncol; 2021; 11(5):e459-e467. PubMed ID: 33476841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.
    Sonnick MA; Oro F; Yan B; Desai A; Wu AJ; Shi W; Zhang Z; Gelblum DY; Paik PK; Yorke ED; Rosenzweig KE; Chaft JE; Rimner A
    Clin Lung Cancer; 2018 Jan; 19(1):e131-e140. PubMed ID: 28756051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.
    Vivekanandan S; Landau DB; Counsell N; Warren DR; Khwanda A; Rosen SD; Parsons E; Ngai Y; Farrelly L; Hughes L; Hawkins MA; Fenwick JD
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):51-60. PubMed ID: 28816160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major adverse cardiac event risk prediction model incorporating baseline Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose in lung cancer (CHyLL).
    Tjong MC; Bitterman DS; Brantley K; Nohria A; Hoffmann U; Atkins KM; Mak RH
    Radiother Oncol; 2022 Apr; 169():105-113. PubMed ID: 35182687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer.
    Contreras JA; Lin AJ; Weiner A; Speirs C; Samson P; Mullen D; Campian J; Bradley J; Roach M; Robinson C
    Radiother Oncol; 2018 Sep; 128(3):498-504. PubMed ID: 29859754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart dose linked with cardiac events and overall survival in lung cancer radiotherapy: A meta-analysis.
    Pan L; Lei D; Wang W; Luo Y; Wang D
    Medicine (Baltimore); 2020 Sep; 99(38):e21964. PubMed ID: 32957314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation.
    Yegya-Raman N; Ho Lee S; Friedes C; Wang X; Iocolano M; Kegelman TP; Duan L; Li B; Berlin E; Kim KN; Doucette A; Denduluri S; Levin WP; Cengel KA; Cohen RB; Langer CJ; Kevin Teo BK; Zou W; O'Quinn RP; Deasy JO; Bradley JD; Sun L; Ky B; Xiao Y; Feigenberg SJ
    Radiother Oncol; 2024 Jan; 190():110005. PubMed ID: 37972736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
    Onimaru R; Shirato H; Shimizu S; Kitamura K; Xu B; Fukumoto S; Chang TC; Fujita K; Oita M; Miyasaka K; Nishimura M; Dosaka-Akita H
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):126-35. PubMed ID: 12694831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    Wang K; Eblan MJ; Deal AM; Lipner M; Zagar TM; Wang Y; Mavroidis P; Lee CB; Jensen BC; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB
    J Clin Oncol; 2017 May; 35(13):1387-1394. PubMed ID: 28113017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer.
    Haque W; Verma V; Fakhreddine M; Butler EB; Teh BS; Simone CB
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):470-477. PubMed ID: 29353659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
    Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
    Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
    Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
    Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.